This company listing is no longer active
Changjiang Runfa Health Industry Past Earnings Performance
Past criteria checks 0/6
Changjiang Runfa Health Industry's earnings have been declining at an average annual rate of -32.8%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been declining at an average rate of 9.8% per year.
Key information
-32.8%
Earnings growth rate
-32.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -9.8% |
| Return on equity | -23.5% |
| Net Margin | -27.7% |
| Next Earnings Update | 28 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Changjiang Runfa Health Industry makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 3,025 | -837 | 849 | 189 |
| 31 Dec 23 | 3,238 | -767 | 954 | 164 |
| 30 Sep 23 | 3,251 | 25 | 876 | 65 |
| 30 Jun 23 | 3,419 | 48 | 900 | 51 |
| 31 Mar 23 | 3,438 | 63 | 885 | 46 |
| 01 Jan 23 | 3,470 | 65 | 908 | 48 |
| 30 Sep 22 | 3,747 | -623 | 996 | 60 |
| 30 Jun 22 | 3,970 | -474 | 1,156 | 63 |
| 31 Mar 22 | 4,229 | -439 | 1,404 | 63 |
| 01 Jan 22 | 4,370 | -413 | 1,582 | 71 |
| 30 Sep 21 | 4,464 | 293 | 1,776 | 54 |
| 30 Jun 21 | 4,428 | 238 | 1,931 | 48 |
| 31 Mar 21 | 4,262 | 264 | 1,881 | 73 |
| 31 Dec 20 | 4,241 | 248 | 1,993 | 69 |
| 30 Sep 20 | 4,440 | -354 | 2,152 | 104 |
| 30 Jun 20 | 4,575 | -380 | 2,219 | 105 |
| 31 Mar 20 | 4,895 | -382 | 2,459 | 109 |
| 31 Dec 19 | 5,073 | -372 | 2,572 | 122 |
| 30 Sep 19 | 5,102 | 340 | 2,530 | 120 |
| 30 Jun 19 | 5,015 | 350 | 2,472 | 142 |
| 31 Mar 19 | 4,860 | 369 | 2,348 | 117 |
| 31 Dec 18 | 4,674 | 367 | 2,226 | 97 |
| 30 Sep 18 | 4,367 | 371 | 2,047 | 86 |
| 30 Jun 18 | 3,939 | 369 | 1,711 | 92 |
| 31 Mar 18 | 3,482 | 346 | 1,346 | 78 |
| 31 Dec 17 | 2,987 | 335 | 885 | 69 |
| 30 Sep 17 | 2,540 | 290 | 538 | 34 |
| 30 Jun 17 | 2,352 | 244 | 407 | 0 |
| 31 Mar 17 | 2,324 | 208 | 349 | 0 |
| 31 Dec 16 | 2,115 | 160 | 306 | 0 |
| 30 Sep 16 | 1,800 | 119 | 224 | 0 |
| 30 Jun 16 | 1,525 | 94 | 160 | 0 |
| 31 Mar 16 | 1,180 | 57 | 84 | 0 |
| 31 Dec 15 | 1,065 | 43 | 63 | 0 |
| 30 Sep 15 | 1,122 | 52 | 64 | 0 |
| 30 Jun 15 | 1,169 | 44 | 65 | 0 |
| 31 Mar 15 | 1,187 | 43 | 67 | 0 |
| 31 Dec 14 | 1,228 | 48 | 66 | 0 |
| 30 Sep 14 | 1,183 | 42 | 63 | 0 |
| 30 Jun 14 | 1,155 | 47 | 62 | 0 |
| 31 Mar 14 | 1,147 | 47 | 58 | 0 |
| 31 Dec 13 | 1,155 | 52 | 58 | 0 |
| 30 Sep 13 | 1,204 | 56 | 60 | 0 |
Quality Earnings: 002435 is currently unprofitable.
Growing Profit Margin: 002435 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002435 is unprofitable, and losses have increased over the past 5 years at a rate of 32.8% per year.
Accelerating Growth: Unable to compare 002435's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 002435 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).
Return on Equity
High ROE: 002435 has a negative Return on Equity (-23.54%), as it is currently unprofitable.